Medigene Ag (MDGEF) 11.8000 $MDGEF Seeking Alph
Post# of 273258
Posted On: 05/18/2015 2:15:55 AM
Medigene Ag (MDGEF) 11.8000 $MDGEF
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.87 (-0.05), MDT: 76.42 (+0.16), CLDX: 25.81 (+0.06), FOMX: 11.41 (+0.09), AMGN: 162.36 (+0.38), AET: 112.74 (+1.26), NKTR: 11.13 (+0.20), CELG: 115.53 (+0.45), HUM: 175.90 (+1.65), CANF: 2.33 (-0.01), ANTM: 161.37 (+1.37), NVO: 56.75 (+0.06), GILD: 109.30 (+0.56), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), CLLS: 32.25 (+0.86), WCG: 83.22 (+0.65), FOLD: 10.53 (+0.03), REGN: 489.01 (-2.42), CUR: 1.70 (-0.04)
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 122.90 (-0.47), JNJ: 102.30 (+0.47), ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)
Primary Biliary Cirrhosis Therapeutics Pipeline Review 2015 - 9 Companies & 10 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h7976j/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Dr. Falk Pharma GmbH - GlaxoSmithKline plc - Intercept Pharmaceuticals, Inc. - Johnson & Johnson - MediGene AG - NGM Biopharmaceuticals, Inc. - Shire Plc - Virobay Inc. Drug Profiles - A-4250 - budesonide - FFP-104 - GSK-2330672 - NGM-282 - obeticholic acid - RhuDex - SHP-625 - ustekinumab - VBY-825 For more information visit http://www.researchandmarkets.com/research/h7...ry_biliary
JNJ: 102.30 (+0.47), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), VBAY: (), GSK: 44.77 (-0.22)
Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Mon Jan 05, 1:30PM CST
The report "Biliary Cirrhosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged. It is most likely an autoimmune disease, where the body's immune system attacks its own cells. It generally strikes women between the ages of 40 and 60. Symptoms of Primary biliary cirrhosis include the following Fatigue, Pruritus, Right upper quadrant discomfort, Hepatomegaly, Hyperpigmentation, Splenomegaly, Jaundice, Xanthelasmata, Sicca syndrome and Kayser-Fleischer rings. Treatment for primary biliary cirrhosis is difficult, because the immune system appears to be involved. Complete Report is Available @ http://www.reportsnreports.com/reports/322822...-2014.html
JNJ: 102.30 (+0.47), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), VBAY: (), GSK: 44.77 (-0.22)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 12.66 (+0.34), INO: 7.97 (-0.02), ADXS: 20.08 (+1.11), GSK: 44.77 (-0.22), NKTR: 11.13 (+0.20), NVS: 103.75 (-0.15)
T-Cell Leukemia Therapeutics Pipeline Review 2014 - 15 Drug Profiles from 10 Leading Pharma Companies
M2 - Wed Sep 10, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shcdvv/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Sanofi - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - Applied Immune Technologies Ltd Drug Profiles - alemtuzumab - mogamulizumab - lenalidomide - PF-03084014 - BMS-906024 - PCI-34051 - NK-314 - Recombinant Protein for CNS, Oncology, Hematological Disorders and Metabolic Disorders - Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease - MMIG-202 - INA-01 - SL-101 - Antibody Targeting HLA-A2 for Neurology, Infectious Diseases and Oncology - Synthetic Peptide for Oncology and Male health - Cell Therapy to Target CD38 for cancer For more information visit http://www.researchandmarkets.com/research/sh...l_leukemia
PCYC: 255.42 (-0.50), PFE: 33.99 (+0.05), BMY: 67.64 (+0.19), STML: 13.43 (-0.17), CELGZ: 2.60 (-0.10)
Seeking Alpha's Biotech Weekly: Biogen's Plaque Attack, Amgen Or Gilead?, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 20, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
TRVN: 6.87 (-0.05), MDT: 76.42 (+0.16), CLDX: 25.81 (+0.06), FOMX: 11.41 (+0.09), AMGN: 162.36 (+0.38), AET: 112.74 (+1.26), NKTR: 11.13 (+0.20), CELG: 115.53 (+0.45), HUM: 175.90 (+1.65), CANF: 2.33 (-0.01), ANTM: 161.37 (+1.37), NVO: 56.75 (+0.06), GILD: 109.30 (+0.56), GERN: 3.89 (-0.02), AZN: 69.29 (-0.81), CLLS: 32.25 (+0.86), WCG: 83.22 (+0.65), FOLD: 10.53 (+0.03), REGN: 489.01 (-2.42), CUR: 1.70 (-0.04)
Medigene AG: Addressing The CAR-T Market Pain Points
Decision Analytics - Seeking Alpha - Wed Mar 18, 11:51AM CDT
I have written about the market opportunity for adoptive cancer immunotherapy before when my interest was piqued by the incredible appreciation of a number of early-stage CAR-T therapy companies (a form of adoptive immunotherapy). Companies such as...
MDVN: 122.90 (-0.47), JNJ: 102.30 (+0.47), ZIOP: 9.17 (-0.17), BLCM: 23.02 (-1.37), KITE: 50.02 (-2.24), JUNO: 43.37 (-1.52), NVS: 103.75 (-0.15)
Primary Biliary Cirrhosis Therapeutics Pipeline Review 2015 - 9 Companies & 10 Drug Profiles
M2 - Tue Mar 03, 6:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/h7976j/primary_biliary) has announced the addition of the "Primary Biliary Cirrhosis - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Primary Biliary Cirrhosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Primary Biliary Cirrhosis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AlbireoPharma - Dr. Falk Pharma GmbH - GlaxoSmithKline plc - Intercept Pharmaceuticals, Inc. - Johnson & Johnson - MediGene AG - NGM Biopharmaceuticals, Inc. - Shire Plc - Virobay Inc. Drug Profiles - A-4250 - budesonide - FFP-104 - GSK-2330672 - NGM-282 - obeticholic acid - RhuDex - SHP-625 - ustekinumab - VBY-825 For more information visit http://www.researchandmarkets.com/research/h7...ry_biliary
JNJ: 102.30 (+0.47), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), VBAY: (), GSK: 44.77 (-0.22)
Biliary Cirrhosis Therapeutic Pipeline Review H2 2014 Report at ReportsnReports.com
PRWeb - Mon Jan 05, 1:30PM CST
The report "Biliary Cirrhosis - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Biliary Cirrhosis. Primary biliary cirrhosis is a long-term liver disease in which the bile ducts in the liver become damaged. It is most likely an autoimmune disease, where the body's immune system attacks its own cells. It generally strikes women between the ages of 40 and 60. Symptoms of Primary biliary cirrhosis include the following Fatigue, Pruritus, Right upper quadrant discomfort, Hepatomegaly, Hyperpigmentation, Splenomegaly, Jaundice, Xanthelasmata, Sicca syndrome and Kayser-Fleischer rings. Treatment for primary biliary cirrhosis is difficult, because the immune system appears to be involved. Complete Report is Available @ http://www.reportsnreports.com/reports/322822...-2014.html
JNJ: 102.30 (+0.47), SHPG: 254.45 (+3.99), ICPT: 306.23 (-0.84), VBAY: (), GSK: 44.77 (-0.22)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 12.66 (+0.34), INO: 7.97 (-0.02), ADXS: 20.08 (+1.11), GSK: 44.77 (-0.22), NKTR: 11.13 (+0.20), NVS: 103.75 (-0.15)
T-Cell Leukemia Therapeutics Pipeline Review 2014 - 15 Drug Profiles from 10 Leading Pharma Companies
M2 - Wed Sep 10, 10:47AM CDT
Research and Markets (http://www.researchandmarkets.com/research/shcdvv/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Sanofi - MediGene AG - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - Applied Immune Technologies Ltd Drug Profiles - alemtuzumab - mogamulizumab - lenalidomide - PF-03084014 - BMS-906024 - PCI-34051 - NK-314 - Recombinant Protein for CNS, Oncology, Hematological Disorders and Metabolic Disorders - Anti-TCR Monoclonal Antibodies for Leukemia and Autoimmune Disease - MMIG-202 - INA-01 - SL-101 - Antibody Targeting HLA-A2 for Neurology, Infectious Diseases and Oncology - Synthetic Peptide for Oncology and Male health - Cell Therapy to Target CD38 for cancer For more information visit http://www.researchandmarkets.com/research/sh...l_leukemia
PCYC: 255.42 (-0.50), PFE: 33.99 (+0.05), BMY: 67.64 (+0.19), STML: 13.43 (-0.17), CELGZ: 2.60 (-0.10)
(0)
(0)Scroll down for more posts ▼